Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST
Go back to Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST| COGENT (NASDAQ: COGT) | Delayed: 36.31 +0.47 (1.31%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $35.84 | 52 Week High | $5.57 | |||
| Open | $35.40 | 52 Week Low | $2.90 | |||
| Day High | $36.90 | P/E | 165.05 | |||
| Day Low | $34.70 | EPS | $0.22 | |||
| Volume | 4,050,450 | |||||
